NITD008 is a selective inhibitor of flaviviruses including dengue virus (EC50 = 0.64 μM), hepatitis C virus and Zika virus, and has also been shown to inhibit tick-borne flaviviruses in vitro. NITD008 has been reported to inhibit RNA-dependent RNA polymerase (RdRp), an essential protein of RNA viruses.
Selective inhibitor of flaviviruses including dengue virus, hepatitis C virus, and Zika virus
There are currently no antiviral therapies available for the tick-borne flaviviruses associated with hemorrhagic fevers: Kyasanur Forest disease virus (KFDV), both classical and the Alkhurma hemorrhagic fever virus (AHFV) subtype, and Omsk hemorrhagic fever virus (OHFV). In this brief study
Proceedings of the National Academy of Sciences of the United States of America, 106(48), 20435-20439 (2009-11-18)
Dengue virus (DENV), a mosquito-borne flavivirus, is a major public health threat. The virus poses risk to 2.5 billion people worldwide and causes 50 to 100 million human infections each year. Neither a vaccine nor an antiviral therapy is currently
Asian Pacific journal of tropical medicine, 10(4), 321-331 (2017-05-30)
Zika virus (ZIKV) is rapidly spreading across the America and its devastating outcomes for pregnant women and infants have driven this previously ignored pathogen into the limelight. Clinical manifestations are fever, joint pain or rash and conjunctivitis. Emergence of ZIKV